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The 2q37 and 17q12-q22 loci are linked to an increased prostate cancer (PrCa) risk. No candidate gene has been localized at
2q37 and the HOXB13 variant G84E only partially explains the linkage to 17q21-q22 observed in Finland. We screened these
regions by targeted DNA sequencing to search for cancer-associated variants. Altogether, four novel susceptibility alleles were
identified. Two ZNF652 (17q21.3) variants, rs116890317 and rs79670217, increased the risk of both sporadic and hereditary
PrCa (rs116890317: OR53.3–7.8, p50.003–3.3 3 1025; rs79670217: OR51.6–1.9, p50.002–0.009). The HDAC4 (2q37.2)
variant rs73000144 (OR514.6, p50.018) and the EFCAB13 (17q21.3) variant rs118004742 (OR51.8, p50.048) were over-
represented in patients with familial PrCa. To map the variants within 2q37 and 17q11.2-q22 that may regulate PrCa-
associated genes, we combined DNA sequencing results with transcriptome data obtained by RNA sequencing. This expression
quantitative trait locus (eQTL) analysis identified 272 single-nucleotide polymorphisms (SNPs) possibly regulating six genes
that were differentially expressed between cases and controls. In a modified approach, prefiltered PrCa-associated SNPs were
exploited and interestingly, a novel eQTL targeting ZNF652 was identified. The novel variants identified in this study could be
utilized for PrCa risk assessment, and they further validate the suggested role of ZNF652 as a PrCa candidate gene. The regu-
latory regions discovered by eQTL mapping increase our understanding of the relationship between regulation of gene expres-
sion and susceptibility to PrCa and provide a valuable starting point for future functional research.
A large proportion of familial prostate cancer (PrCa) cases
can be explained by genetic risk factors.1 Despite extensive
research, the identiﬁcation of these factors has proven chal-
lenging. In Finland, mutations in hereditary prostate cancer
(HPC) risk genes are relatively rare, with the exception of the
HOXB13 G84E mutation,2 which is present in 8.4% of fami-
lial PrCa cases and has been signiﬁcantly associated with an
increased PrCa risk in unselected cases.3
The involvement of chromosomal regions 2q37 and
17q12-q22 with PrCa has been previously reported in numer-
ous linkage4–6 and genome-wide association studies
(GWASs).7,8 Cropp et al.9 performed a genome-wide linkage
scan of 69 Finnish high-risk HPC families and in the domi-
nant model, the loci on 2q37.3 and 17q21-q22 exhibited the
strongest linkage signals. No known PrCa candidate gene
resides on 2q37.3, and as demonstrated in our earlier study,
the HOXB13 G84E mutation only partially explains the
observed linkage to 17q21-q22.3
Here, we performed targeted resequencing that covered
the linkage peaks on 2q37 and 17q11.2-q22. The sequence
data were ﬁltered to identify the variants within genes pre-
dicted to be involved in PrCa predisposition. These variants
were validated in Finnish HPC families and in unselected
PrCa patients by Sequenom genotyping, and several novel
variants were discovered that were signiﬁcantly associated
with PrCa. To study the impact of single-nucleotide polymor-
phisms (SNPs) on the regulation of gene expression within
the two linked regions, we performed transcriptome sequenc-
ing followed by expression quantitative trait loci (eQTL)
mapping. eQTLs are known to modify the penetrance of rare
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deleterious variants and therefore likely contribute to genetic
predisposition to complex diseases. New information was
obtained on several genes as well as their regulatory elements
that generated fresh insights into PrCa susceptibility, espe-
cially in HPC.
Material and Methods
All of the subjects were of Finnish origin. The samples were
collected with written and signed informed consent. The can-
cer diagnoses were conﬁrmed using medical records and the
annual update from the Finnish Cancer Registry. The project
was approved by the local research ethics committee at Pir-
kanmaa Hospital District and by the National Supervisory
Authority for Welfare and Health.
Targeted resequencing of 2q37 and 17q11.2-q22
Based on the linkage analysis results from Cropp et al.,9 63
PrCa patients and ﬁve unaffected individuals belonging to 21
Finnish high-risk HPC families10 were selected for targeted
resequencing of the 2q37 and 17q11.2-q22 regions (Support-
ing Information Table S1). Each family had at least three
ﬁrst- or second-degree relatives diagnosed with PrCa. Paired-
end next generation sequencing was performed at the Tech-
nology Centre, Institute for Molecular Medicine Finland
(FIMM), University of Helsinki. The sequenced fragments
spanned approximately 6.8 Mb for chromosome 2q and 21.6
Mb for 17q. The target regions were captured using SeqCap
EZ Choice array probes (Roche NimbleGen, Madison, WI)
and were sequenced on a Genome Analyzer IIx (Illumina,
San Diego, CA) following the manufacturer’s protocol. The
read alignment and variant calling were performed according
to FIMM’s Variant-Calling Pipeline (VCP).11
Bioinformatics workflow for variant characterization
A schematic overview of our bioinformatics workﬂow is
shown in Figure 1. Only those variants that were present in
all the affected family members were selected for subsequent
analysis. The variants were annotated using Ensembl V65
gene set retrieved from the UCSC Genome Browser.12 The
phenotypic effects of the variants were studied with three in
silico pathogenicity prediction programs. MutationTaster13
classiﬁes single-nucleotide variants (SNVs) and small inser-
tion/deletion polymorphisms (indels) as polymorphic or
pathogenic. PolyPhen-214 and PON-P15 only predict the
effects of nonsynonymous SNVs that result in amino acid
replacement. PolyPhen-2 classiﬁes the variants as benign,
possibly pathogenic or probably pathogenic, whereas PON-P
deﬁnes them as neutral, unclassiﬁed or pathogenic. Variants
categorized as pathogenic by at least one tolerance predictor
were deﬁned as pathogenic. In addition, minor allele frequen-
cies (MAFs) were obtained from the dbSNP database and
information on known PrCa-associated genes was retrieved
from the COSMIC16 and DDPC17 databases. Pathway data
were gathered from Pathway Commons,18 KEGG19 and
WikiPathways20 and Gene Ontology data were retrieved from
Ensembl BioMart v.65.21 Higher priority was assigned to rare
variants (MAF <0.05), variants located in genes previously
linked to PrCa, and variants located in genes functionally
similar to PrCa-associated genes.
Validation of predicted PrCa-associated variants with
Sequenom
After ﬁltering, 58 variants in 35 target genes (listed in Sup-
porting Information Tables S2–S4) were selected for valida-
tion which was performed on germline DNA from 2,216
subjects, including 1,293 cases and 923 population controls.
The majority of the cases (1,105 individuals) represented
Figure 1. A flowchart describing the variant characterization pipe-
line. The targeted resequencing of 2q37 and 17q11.2-q22 from 68
Finnish HPC family members produced a total of 107,479 unique
sequence variants. Family-based filtering excluded 66,867 variants
that did not cosegregate with affection status. Annotation enabled
the selection of 24,813 variants that were located within protein-
coding genes. Pathogenicity predictions were performed in silico
using MutationTaster, PolyPhen-2 and PON-P. As a result, the num-
ber of candidate variants was reduced to 152. The final filtering
step exploited diverse information on genes and variants as well
as gene ontology and pathway data stored in several public data-
bases. In addition, select HDAC4, ZNF652 and HOXB13 variants,
which were predicted to be nonpathogenic, were included in the
validation because these genes have been associated with PrCa in
previous studies.
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unselected PrCa patients from the Pirkanmaa Hospital Dis-
trict, Tampere, Finland. In addition, 188 index cases from
Finnish HPC families10 were included in the study. The con-
trol DNA samples from anonymous male blood donors were
provided by the Finnish Red Cross Blood Transfusion Serv-
ice. Genotyping was performed at the Technology Centre,
FIMM using the Sequenom MassARRAY system and iPLEX
Gold assays (Sequenom, San Diego, CA). Genotyping reac-
tions were performed with 20 ng of dried genomic DNA
according to manufacturer’s recommendations and with their
reagents. The genotypes were called using TyperAnalyzer
software (Sequenom). For quality control (QC) reasons, the
genotype calls were also checked manually. Genotyping qual-
ity was examined using a detailed QC procedure that
included success rate checks, duplicated samples and water
controls.
Statistical and bioinformatic analyses of the validated
variants
Association and Hardy-Weinberg equilibrium (HWE) tests
were performed using PLINK.22 The p value threshold for
the HWE test was set to 0.05. Samples with low genotyping
frequencies (<0.80) were excluded from the association anal-
ysis. The statistical signiﬁcance of the association was eval-
uated using a two-sided Fisher’s exact test. Odds ratios (OR)
were calculated using PLINK with option — ﬁsher. No fur-
ther model adjustments for confounding factors were made.
ENCODE information23 for noncoding variants was retrieved
from the Regulome database (RegulomeDB).24 The linkage
disequilibrium (LD) analysis of the statistically signiﬁcant
variants is described in Supplementary Methods.
Genotyping of the top four candidate variants in Finnish
HPC families
Four variants were chosen for segregation analysis in Finnish
HPC families based on a strong association with PrCa, a
high OR value and/or predicted pathogenicity. The cosegre-
gation of rs116890317 and rs79670217 in ZNF652 (RefSeq
NM_001145365), rs73000144 in HDAC4 (RefSeq
NM_006037) and rs118004742 in EFCAB13 (RefSeq
NM_152347) with affection status was determined in 41 fam-
ilies whose index cases were mutation-positive in the Seque-
nom validation. For these families, DNA samples were
available from 243 PrCa cases and 204 healthy family mem-
bers. The variants were genotyped in two to 17 (median:
seven) individuals per family by Sanger sequencing.
RNA extraction and sequencing
Peripheral blood samples collected in PAXgeneV
R
Blood RNA
Tubes (PreAnalytiX GmbH, Switzerland) were available from
84 PrCa patients and 15 healthy male relatives belonging to
31 Finnish HPC families. These included 11 families from
the targeted resequencing step (Supporting Information Table
S1) and additional 20 high-risk families.10 Total RNA was
puriﬁed with MagMAXTM for Stabilized Blood Tubes RNA
Isolation Kit (AmbionV
R
/Life Technologies, Carlsbad, CA) and
with a PAXgene Blood miRNA Kit (PreAnalytiX GmbH).
RNA integrity and quality were analyzed using the Agilent
2100 Bioanalyzer and the Agilent RNA 6000 Nano Kit (Agi-
lent Technologies, Santa Clara, CA). The massively parallel
paired-end RNA sequencing was performed at Beijing
Genomics Institute (BGI Hong Kong Co., Tai Po, Hong
Kong) using an Illumina HiSeq2000 sequencing platform
(Illumina).
RNA sequencing data analysis
On average, RNA sequencing produced 45 million reads per
sample. The QC check was performed using fastQC (http://
www.bioinformatics.bbsrc.ac.uk/projects/fastqc). The reads
were aligned with Tophat225 using GRCh37/hg19 as the ref-
erence genome. The read counts for the genes were deter-
mined using HTSeq (http://www-huber.embl.de/users/anders/
HTSeq/). The raw read counts were transformed into compa-
rable expression values via normalization using the DESeq
package for R26 and the genes with very low or no expression
(normalized read counts of <20) were removed. A differen-
tial gene expression analysis was then performed using a
two-sided Mann–Whitney test with a p value cutoff of 0.05.
eQTL mapping and data analysis
The eQTL analysis was based on the RNA-seq data and on
the SNP genotypes obtained from targeted DNA sequencing.
This data existed for 19 samples at 2q37 and for 17 samples
at 17q11.2-q22. In total, 54,919 SNPs (average 6,865 per
gene, see Supporting Information Table S5 for details) were
tested for association with their candidate target genes. Only
genes with differential expression (DE) patterns between
health status groups were included in the eQTL analysis, to
increase the probability that found SNP-gene associations
also link PrCa with a certain SNP genotype. The eQTL map-
ping was applied on 2q37 and 17q11.2-q22 to identify cis-
regulated genes. SNPs associated in cis were deﬁned as var-
iants located within 1 Mb up- or downstream of the gene
under study. The signiﬁcance level for SNP-gene associations
was set to p 0.005. A multiple testing adjustment was omit-
ted because of the large number of tested SNPs and the
nature of the permutation type tests, acknowledging that this
resulted in compromised resolution.
A modiﬁed cis-eQTL approach was also utilized, wherein
a large genotype dataset from the iCOGS study27 was used to
preidentify possible PrCa-associated SNPs for 2,824 unse-
lected Finnish PrCa patients and 2,440 controls. Here, Fish-
er’s exact test with a modest signiﬁcance level of 0.005 was
used to study the association. Signiﬁcant iCOGS variants that
were also observed in the targeted DNA sequencing data
were then selected for eQTL analysis, which was restricted to
the ﬁne-mapped regions. Additional details for the eQTL
analysis are presented in Supplementary Methods.
RegulomeDB was used to annotate and assess the regula-
tory potential of the detected eQTLs.24 The ENCODE
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datasets23 were retrieved from the UCSC Genome Browser
website for visualization purposes using the Table Browser
tool.12 As a general indicator of regulatory potential, we used
the dataset that contained enriched DNase hypersensitive
sites in 125 cell types. To highlight the regulatory potential of
eQTLs in PrCa tissue, we used the LNCaP DNase (wgEnco-
deAwgDnaseUwDukeLncapUniPk) and LNCaP (Andr)
DNase (wgEncodeAwgDnaseUwDukeLncapandrogenUniPk)
datasets containing DNase hypersensitive sites in LNCaP cells
under normal and androgen-induced conditions, respectively.
Transcription factor (TF) binding site data were gathered
from the Txn Fac ChIP V3 dataset, which contains ChIP-seq
experimental data on 91 cell types and 189 TFs.
Results
Targeted DNA sequencing data analysis
The percentage of mapped reads was 95.0 and 95.7% for the
samples sequenced for 2q37 and 17q11.2-q22, respectively. The
target coverage was 99.8% for 2q37 and 99.5% for 17q11.2-q22.
Correspondingly, the percentage of bases having coverage of
203 or more was 79.9 and 63.4%. The total number of unique
variants across all samples discovered by the utilized VCP was
107,479 (Fig. 1). Among the 41 predicted pathogenic variants
in 2q37, there were 20 missense SNVs, 16 noncoding SNVs
and ﬁve indels. Of all 111 predicted pathogenic variants in
17q11.2-q22, two variants were nonsense SNVs, 49 were mis-
sense SNVs, 36 were noncoding SNVs and 24 were indels.
PrCa-associated variants identified by Sequenom
validation
Following prioritization, a total of 58 variants were selected
for validation in a larger sample set (Supporting Information
Table S2). In the QC analysis, four variants failed the HWE
test (p< 0.05), and 20 samples were omitted due to low gen-
otyping frequencies (<0.80). In the case-control association
analysis, a total of 13 variants in seven different genes were
statistically signiﬁcantly associated with PrCa (p< 0.05;
Tables 1 and 2 and Supporting Information Tables S3 and
S4). Three variants were located in the ZNF652 gene at
17q21.3, and the HDAC4 (2q37.2), HOXB3 (17q21.3),
ACACA (17q21) and MYEOV2 (2q37.3) genes harbored two
variants each. A single variant was identiﬁed in the HOXB13
and EFCAB13 genes at 17q21.3. Only three of these 13 PrCa-
associated variants were located within exons, whereas the
majority, 10 variants, resided in noncoding regions.
Four of the variants with a statistically signiﬁcant associa-
tion with PrCa were present in both the familial and the
unselected sample sets. These were rs116890317 and
rs79670217 in ZNF652, rs10554930 in HOXB3 and
rs13411615 in MYEOV2. The two ZNF652 variants had the
strongest association with an increased PrCa risk.
rs116890317 had the most signiﬁcant association with the
familial cases (OR5 7.8, 95% CI 3.0–20.3, p5 3.3 3 1025)
and the same variant conferred the highest risk of 3.3 (95%
CI 1.4–7.5, p5 0.003) among the unselected cases.
rs79670217 had the most signiﬁcant association with PrCa in
the unselected sample set (p5 0.002) and was the second
most signiﬁcant variant in the familial PrCa patients
(OR5 1.9, 95% CI 1.2–3.1, p5 0.009; Tables 1 and 2).
The highest OR of 14.6 (95% CI 1.5–140.2, p5 0.018) was
observed for the HDAC4 variant rs73000144 (c.958C>T,
p.Val320Ile) among the familial samples (Table 1). Only three
familial PrCa patients (1.6%), seven unselected patients
(0.6%) and one control individual (0.1%) carried the minor
allele in a heterozygous state, and none of the genotyped
individuals were homozygous. rs73000144 was predicted to
Table 1. Variants significantly associated with prostate cancer based on a comparison of familial cases (n5186) and controls (n5914)
SNP Id Function Gene Chr Min/Maj F_A/F_U (%) p value OR (95% CI) Pathogenicity prediction
rs116890317 Intronic ZNF652 17 A/T 2.96/0.39 3.3 3 1025 7.8 (3.0–20.3) Polymorphism/–/–
rs79670217 Intronic ZNF652 17 G/T 6.65/3.56 0.009 1.9 (1.2–3.1) Polymorphism/–/–
rs10554930 Intronic HOXB3 17 2ACA/ACA 27.5/21.3 0.010 1.4 (1.1–1.8) Pathogenic/–/–
rs35384813 50-UTR HOXB3 17 1T/– 26.7/20.8 0.013 1.4 (1.1–1.8) Pathogenic/–/–
rs73000144 Missense HDAC4 2 T/C 0.80/0.06 0.018 14.6 (1.5–140.2) Polymorphism/benign/neutral
rs134116151 Near gene 50 MYEOV2 2 C/A 52.1/45.6 0.023 1.3 (1.0–1.6) Polymorphism/–/–
rs9899142 Intronic HOXB13 17 T/C 11.2/15.6 0.031 0.7 (0.5–1.0) Polymorphism/–/–
rs118004742 Nonsense EFCAB13 17 G/T 4.79/2.73 0.048 1.8 (1.0–3.1) Pathogenic/–/–
rs142044482 30-UTR ZNF652 17 1A/– 2.94/1.59 0.087 1.9 (0.9–3.8) Polymorphism/–/–
rs1406113631 Near gene 50 ACACA 17 2A/A 28.8/31.1 0.421 0.9 (0.7–1.1) Pathogenic/–/–
rs728282461 Near gene 50 ACACA 17 G/A 28.8/30.9 0.459 0.9 (0.7–1.2) Pathogenic/benign/neutral
rs134064101 Near gene 50 MYEOV2 2 C/T 47.6/46.8 0.817 1.0 (0.8–1.3) Pathogenic/–/–
rs61752234 Synonymous HDAC4 2 C/T 7.22/6.83 0.823 1.1 (0.7–1.6) Polymorphism/–/–
Bold signifies p<0.05.
1Variants are in linkage disequilibrium.
Abbreviations: Chr: chromosome; Min: minor allele; Maj: major allele; F_A: frequency of the minor allele in cases; F_U: frequency of the minor allele
in controls; OR: odds ratio; CI: confidence interval; pathogenicity prediction results from: MutationTaster/PolyPhen-2/Pon-P.
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be benign or neutral by all three in silico pathogenicity pre-
diction algorithms (Supporting Information Table S2).
The rs118004742 nonsense mutation (c.1638T>G,
p.Tyr546Ter) in the EFCAB13 gene was predicted to be path-
ogenic by MutationTaster (Supporting Information Table S2).
Three familial cases (1.6%) were homozygous for the minor
allele. There were 12 heterozygotes among the familial index
cases (6.5%) and 66 among the unselected cases (6.0%). A
statistically signiﬁcant association between rs118004742 and
PrCa was only observed for the familial patients (Table 1).
The OR of 1.8 (95% CI 1.0–3.1) suggested an increased risk
of HPC. rs118004742 carriers in the unselected sample set
did not have an increased cancer risk (OR5 1.1, 95% CI 0.8–
1.6, p5 0.637; Supporting Information Table S4).
Two common noncoding variants in the HOXB3 gene,
rs10554930 and rs35384813, had a moderate effect on PrCa
risk, with ORs ranging from 1.2 to 1.4 (Tables 1 and 2).
MutationTaster predicted both of these variants to be patho-
genic (Supporting Information Table S2). For ﬁve variants,
the ORs were< 1.0, indicating a modulatory role in PrCa
predisposition. These variants were located near or within
the ZNF652, HDAC4, HOXB13 and ACACA genes (Tables 1
and 2). According to the RegulomeDB, three of the 13 statis-
tically signiﬁcant variants were likely to affect protein bind-
ing: rs9899142 in HOXB13 (Regulome score of 1f),
rs13406410 in MYEOV2 and rs72828246 in ACACA (both
having Regulome score of 2b).
In case-case comparisons, none of the identiﬁed variants
were signiﬁcantly associated with Gleason score, average age
or the serum prostate speciﬁc antigen (PSA) level at diagnosis
(data not shown). The LD analysis (Supporting Information
Fig. S1) revealed that none of our 13 statistically signiﬁcant
variants (Tables 1 and 2) were in linkage disequilibrium with
previously reported PrCa-associated variants27 (see Supple-
mentary Results for details).
Segregation analysis of the top four candidate variants
Altogether, 41 familial index cases out of 188 genotyped by
Sequenom carried at least one of the top four candidate var-
iants. Segregation analysis was performed for these 41 HPC
families. rs116890317, rs79670217 and rs118004742 were
more common among PrCa patients than healthy family
members and provided evidence for cosegregation with affec-
tion status in 20 families (Supporting Information Tables S6–
S8). However, in 15 of these families, unaffected male muta-
tion carriers were also observed. In seven families, all of the
unaffected male carriers were young enough (<55 years) to
develop PrCa later in life. rs116890317 segregated completely
with affection status in one family (Supporting Information
Fig. S2a), as did rs79670217 (Supporting Information Fig.
S2b). Complete segregation of rs118004742 was observed in
three families (Supporting Information Table S8). The
HDAC4 variant rs73000144 was detected in three families,
and approximately one-third of the family members were
identiﬁed as carriers, irrespective of their health status (Sup-
porting Information Table S9).
Multiple variants were observed in 16 individuals from 14
families. Two families harbored rs116890317, rs79670217 and
rs118004742, whereas one family was positive for
rs79670217, rs73000144 and rs118004742. In the remaining
families, the most common combination detected was
rs79670217 together with rs118004742 (six families). Evi-
dence for segregation with affection status was obtained for a
maximum of one variant per family.
Table 2. Variants significantly associated with prostate cancer based on a comparison of unselected cases (n51096) and controls (n5914)
SNP Id Function Gene Chr Min/Maj F_A/F_U (%) p value OR (95% CI) Pathogenicity prediction
rs79670217 Intronic ZNF652 17 G/T 5.66/3.56 0.002 1.6 (1.2–2.2) Polymorphism/–/–
rs116890317 Intronic ZNF652 17 A/T 1.27/0.39 0.003 3.3 (1.4–7.5) Polymorphism/–/–
rs134064101 Near gene 50 MYEOV2 2 C/T 51.5/46.8 0.006 1.2 (1.1–1.4) Pathogenic/–/–
rs61752234 Synonymous HDAC4 2 C/T 4.85/6.83 0.008 0.7 (0.5–0.9) Polymorphism/–/–
rs142044482 30-UTR ZNF652 17 1A/- 0.68/1.59 0.009 0.4 (0.2–0.8) Polymorphism/–/–
rs1406113631 Near gene 50 ACACA 17 2A/A 27.9/31.1 0.032 0.9 (0.7–1.0) Pathogenic/–/–
rs10554930 Intronic HOXB3 17 2ACA/ACA 24.1/21.3 0.034 1.2 (1.0–1.4) Pathogenic/–/–
rs134116151 Near gene 50 MYEOV2 2 C/A 49.0/45.6 0.037 1.1 (1.0–1.3) Polymorphism/–/–
rs728282461 Near gene 50 ACACA 17 G/A 28.0/30.9 0.044 0.9 (0.8–1.0) Pathogenic/benign/neutral
rs35384813 50-UTR HOXB3 17 1T/– 23.2/20.8 0.073 1.1 (1.0–1.3) Pathogenic/–/–
rs73000144 Missense HDAC4 2 T/C 0.33/0.06 0.078 5.9 (0.7–47.9) Polymorphism/benign/neutral
rs118004742 Nonsense EFCAB13 17 G/T 3.0/2.7 0.637 1.1 (0.8–1.6) Pathogenic/–/–
rs9899142 Intronic HOXB13 17 T/C 16.1/15.6 0.665 1.0 (0.9–1.2) Polymorphism/–/–
Bold signifies p<0.05.
1Variants are in linkage disequilibrium.
Abbreviations: Chr: chromosome; Min: minor allele; Maj: major allele; F_A: frequency of the minor allele in cases; F_U: frequency of the minor allele
in controls; OR: odds ratio; CI: confidence interval; pathogenicity prediction results from: MutationTaster/PolyPhen-2/Pon-P.
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eQTL mapping results
Differential gene expression analysis revealed three genes (of
173 tested) located at 2q37 and ﬁve genes (of 761 tested) at
17q11.2-q22 whose expression levels differed signiﬁcantly
between cases and controls (p< 0.05). In the targeted cis-
eQTL analysis, SNPs within 2 Mb windows were tested for
association with each of these eight DE genes (Supporting
Information Table S5). Altogether, 272 candidate regulatory
SNPs were identiﬁed for six DE genes only (Supporting
Information Table S10). A vast majority, 237 candidate SNPs
potentially regulate the expression of AGAP1, SCLY and
NDUFA10 at 2q37 (Fig. 2). The remaining 35 candidate
SNPs possibly regulate TBKBP1, PNPO and NAGS at
17q11.2-q22 (Fig. 3). Based on the ENCODE data, the
strongest evidence for regulatory potential was found for
rs11650354 on chromosome 17, which targets the TBKBP1
Figure 2. Cis-eQTLs targeting differentially expressed genes on chromosome 2. All statistically significant eQTLs are indicated with a track of
black bars. Selected eQTLs, rs12620966 and rs983221 (targeting AGAP1) and rs1996513 and rs12712297 (targeting NDUFA10) are illus-
trated in more detail. DNaseI hypersensitive sites from the DNase cluster and LNCaP datasets are indicated with green and red rectangles,
respectively. Blue rectangles denote TF binding sites.
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gene. This known eQTL overlaps with an open chromatin
region (Mcf7 and Gm12892 cell lines) and its role in the reg-
ulation of TBKBP1 expression has been conﬁrmed in a previ-
ous study.28 rs12620966 targeting AGAP1 on chromosome 2
overlaps with several TF binding sites discovered by ChIP-
seq (HepG2 cell line), position weight matrix (PWM) match-
ing and digital DNaseI footprinting studies (Supporting
Information Table S10). None of the coding variants that
were identiﬁed by targeted DNA sequencing and validated by
Sequenom were statistically signiﬁcant eQTLs (data not
shown).
The modiﬁed cis-eQTL analysis was based on 12 SNPs at
2q37 and 22 SNPs at 17q11.2-q22 that were shared between
the iCOGS dataset and our set of variants obtained by tar-
geted resequencing. The regulatory potential of these 34
SNPs was evaluated for 144 genes at 2q37 and for 160 genes
Figure 3. Cis-eQTLs targeting differentially expressed genes on chromosome 17. All statistically significant eQTLs are indicated with a track
of black bars. Selected eQTLs, rs11650354 (targeting TBKBP1) and rs12951323 (targeting PNPO) are illustrated in more detail. DNaseI
hypersensitive sites from the DNase cluster and LNCaP datasets are indicated with green and red rectangles, respectively. Blue rectangles
denote TF binding sites.
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at 17q11.2-q22. The modiﬁed eQTL approach identiﬁed only
one PrCa-associated candidate eQTL on chromosome 2 and
36 candidate eQTLs on chromosome 17. Selected examples
of these eQTLs and their target genes are shown in Support-
ing Information Table S11. The ENCODE data from Regulo-
meDB indicated the strongest evidence of regulatory
potential for two variants on chromosome 17, rs4796751 and
rs4796616, which target the DHX58, MLX and JUP genes.
Both variants have previously been reported as eQTLs target-
ing MGC20781 and NT5C3L29 and they overlap with open
chromatin regions (in 16 and 17 cell lines, respectively).
rs4796616 is also located within a TF binding site (U2OS cell
line). Two additional chromosome 17 variants, rs4793943
and rs16941107 were deﬁned as likely to affect gene expres-
sion. These variants target the ZNF652 and ARL17B genes,
respectively, and overlap with open chromatin regions (in 6
and 42 cell lines, respectively) as well as several TF binding
sites (Supporting Information Table S11). Of particular inter-
est was the chromosome 17 variant rs4793976 targeting the
SPOP gene. Although no data for this eQTL was available in
the RegulomeDB, the importance of SPOP in PrCa predispo-
sition has been recognized.30
Discussion
Prior studies have identiﬁed a strong relationship between
PrCa and linkage to chromosomal regions 2q37 and 17q11.2-
q22. Inspired by the lack of candidate genes and mutations,
we resequenced the linkage peaks and conﬁrmed the
sequencing results by validating select variants. As the num-
ber of variants provided by the VCP was high, their prioriti-
zation for validation was critical.
The variants that were statistically signiﬁcantly associated
with PrCa were clustered in two genes on chromosome 2q37,
HDAC4 and MYEOV2, and in ﬁve genes on chromosome
17q11.2-q22, ZNF652, HOXB3, HOXB13, EFCAB13 and
ACACA (Tables 1 and 2). Interestingly, four of these genes,
HDAC4, ZNF652, HOXB3 and HOXB13 encode TFs. Tran-
scriptional regulation plays an essential role in maintaining
normal gene control, and mutations in genes coding for TFs
have been identiﬁed in PrCa. Examples of commonly occur-
ring alterations include the fusion of TMPRSS2 with ERG,
and mutations in genes coding for the forkhead-box family
of TFs.31
The ZNF652 gene at 17q21.3 codes for a DNA-binding
transcriptional repressor protein with seven zinc ﬁnger
motifs.32 Highest expression levels have been detected in nor-
mal breast, prostate and pancreas, whereas in primary tumors
and cancer cell lines, ZNF652 expression is generally lower.32
However, in PrCa, the coexpression of high levels of ZNF652
and the androgen receptor (AR) has been shown to increase
the risk of PSA relapse.33 In addition, the recently character-
ized ZNF652 DNA binding site was found in the promoters
of several genes that are involved in PrCa development and
progression.34 ZNF652 also interacts with CBFA2T3, a puta-
tive breast cancer tumor suppressor, which has been shown
to enhance the repressor activity of ZNF652.32
To date, only a single PrCa-associated risk variant has
been identiﬁed in the ZNF652 gene. rs7210100 has been
reported to predispose men of African descent to PrCa. The
risk allele is present at a low frequency (<1%) in non-
African populations.35 A possible European-speciﬁc risk vari-
ant, rs11650494, is located in a lincRNA just downstream of
the ZNF652 gene and was recently described by the PRACTI-
CAL Consortium.27 The present study identiﬁed two novel
ZNF652 gene variants, rs116890317 and rs79670217, which
were signiﬁcantly associated with PrCa in both familial and
unselected cases. The risk association was particularly appa-
rent in patients with a positive family history of the disease.
Correspondingly, both variants showed evidence for at least
partial cosegregation with affection status in a substantial
portion of Finnish HPC families. Like rs7210100, these two
novel variants are located in the ﬁrst intron of the gene, sug-
gesting that they may play a role in regulating ZNF652 by
affecting splicing events and/or tissue-speciﬁc expression.
The HDAC4 gene at 2q37.2 encodes a well-characterized
transcriptional repressor. HDAC4 has been reported to accu-
mulate in the nucleus in hormone-refractory PrCa36 and to
bind to and inhibit the activity of AR by SUMOylation.37
Here, we determined that the exonic HDAC4 variant
rs73000144 (c.958C>T) was signiﬁcantly associated with fam-
ilial PrCa (OR5 14.6, 95% CI 1.5–140.2, p5 0.018). The var-
iant also had a high OR (55.8, 95% CI 0.7–47.9) among the
unselected cases (Supporting Information Table S4), suggest-
ing an increased cancer risk, but this result was not statisti-
cally signiﬁcant (p5 0.078). The pathogenicity of rs73000144
is uncertain. The resulting amino acid change, a substitution
of isoleucine for valine (p.Val320Ile) is conservative and was
not considered pathogenic by any of the in silico predictors
used (Supporting Information Table S2). The strikingly high
OR for the familial sample set, together with the observation
that this variant was detected in only three out of 186 index
cases from the Finnish HPC families, suggested that
rs73000144 may be a private mutation. The importance of
private mutations has been emphasized in many diseases,
some of which are associated with speciﬁc ethnic groups.
The protein encoded by the EFCAB13 (EF-hand calcium
binding domain 13) gene at 17q21.3 contains a particular
helix-loop-helix domain, the EF-hand, which is required for
calcium ion binding. EF-hands are often found in calcium
sensor and calcium signal modulator proteins. Ca21 binding
triggers a conformational change in the EF-hand motif,
which leads to the activation or inactivation of target pro-
teins. Currently, there is no evidence linking EFCAB13 with
PrCa. The nonsense mutation rs118004742 in the EFCAB13
gene introduces a premature stop codon, leading to a signiﬁ-
cant truncation of the nascent protein. Truncating mutations
are generally considered deleterious and, as expected,
rs118004742 was predicted pathogenic by MutationTaster
(Supporting Information Table S2). The variant segregated
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completely with affection status in three Finnish mutation-
positive HPC families and showed evidence for partial cose-
gregation in four additional families. In these seven families,
the variant was observed in all of the patients but in only
half of the genotyped unaffected men (Supporting Informa-
tion Table S8). It is possible that rs118004742 contributes to
hereditary, but not sporadic, disease. Once a more detailed
characterization of the EFCAB13 protein function is avail-
able, it will be possible to assess the indicative role of
EFCAB13 as a PrCa risk gene more accurately.
Considering the importance of the HOXB13 variant
G84E2 in familial PrCa predisposition, we compared the fam-
ilies that were positive for the top four SNPs with the exist-
ing G84E genotyping data.3 Interestingly, ten of the 11
families that were positive for the ZNF652 variant
rs116890317 also harbored G84E. In these ten families, 12/21
(57%) of PrCa patients carried both the rs116890317 variant
and the HOXB13 variant G84E. Cosegregation of the ZNF652
variant rs79670217 (Supporting Information Table S7) and
G84E was detected in 6/42 (14%) of affected individuals, and
among the 31 PrCa patients carrying the EFCAB13 variant
rs118004742 (Supporting Information Table S8), G84E was
identiﬁed in only 2 (6%) patients. In addition, one of the
three PrCa patients carrying the HDAC4 variant rs73000144
also carried G84E. The co-occurrence of the ZNF652 variant
rs116890317 with the HOXB13 variant G84E suggests possi-
ble interaction between these two genomic regions and is an
interesting issue for future research.
The HOXB3 gene belongs to the same evolutionarily con-
served HOXB gene family at 17q21-q22 as HOXB13.
Recently, HOXB3 overexpression was observed in primary
PrCa tissues, predicting poor survival.38 In our study, two
possibly pathogenic HOXB3 variants were associated with a
moderately increased PrCa risk, rs10554930 in both datasets
and rs35384813 in the familial sample set only (Tables 1 and
2). rs10554930 is intronic, located 730 bp upstream of the
HOXB3 transcription start site (TSS), whereas rs35384813 is
in the 50-UTR of the gene. Most variants affecting the expres-
sion level of a particular gene are located near the TSS of
that gene29 making it possible that these two variants partici-
pate in the regulation of HOXB3 gene expression.
The ENCODE data supported a possible regulatory role
for three of the statistically signiﬁcant noncoding variants
validated by Sequenom. The intronic HOXB13 variant
rs9899142 likely affects the binding of ZNF263, a transcrip-
tional repressor that participates in cell structure maintenance
and proliferation.39 This variant is also a known cis-eQTL
that regulates the expression of the SKAP1 gene which has
been associated with PrCa-speciﬁc mortality.40 The SNPs
rs13406410 and rs72828246 are located near the 50 ends of
the MYEOV2 and ACACA genes, respectively. Both of these
variants likely affect the binding of E2F1. This TF plays a
central role in DNA damage-induced apoptosis and DNA
repair.41 Recently, a strong correlation between E2F1 and
increased expression of NuSAP, a protein that binds DNA to
the mitotic spindle, was observed in recurrent PrCa.42 The
minor alleles of rs9899142, rs13406410 and rs72828246 had a
low OR and were present at a high frequency in both cases
and controls. Nevertheless, according to the common dis-
ease–common variant hypothesis, it is possible that the major
alleles, rather than the minor alleles, explain a proportion of
PrCa susceptibility.
The eQTL mapping enabled us to identify genomic
regions that were likely to be regulated by variants in the
2q37 and 17q11.2-q22 loci. A drawback of the eQTL analysis
was the use of peripheral blood for RNA-sequencing. How-
ever, fresh PrCa tissue is rarely available and, due to the mul-
tifocal nature of PrCa, the quality of prostate biopsies may be
compromised. Postmortem material, on the other hand, rep-
resents expression proﬁles typical for end-stage disease,
whereas our aim was to identify inherited mutations predis-
posing their carriers to PrCa. Therefore, we consider blood to
be a valid starting point for expression proﬁling of the early
changes in PrCa. It will be exciting to see whether future
studies conﬁrm our results in another, independent sample
set, preferably a collection of PrCa tissue samples.
The traditional eQTL analysis identiﬁed six DE genes that
were putatively regulated by eQTLs in cis (Figs. 2 and 3; Sup-
porting Information Table S10). None of these genes has pre-
viously been associated with PrCa. The protein encoded by the
AGAP1 gene is involved in membrane trafﬁcking and cytoskel-
eton dynamics.43 SCLY and PNPO participate in metabolic
processes, SCLY in the decomposition of L-selenocysteine44
and PNPO in the biosynthesis of vitamin B6. The adaptor pro-
tein encoded by TBKBP1 plays a role in the TNF-alpha/NF-
kappa B signal transduction pathway.45 NDUFA10 and NAGS
are mitochondrial enzymes. NDUFA10, a member of the
respiratory chain complex I, is responsible for electron trans-
port.46 NAGS catalyzes the formation of N-acetylglutamate, an
activator of urea cycle enzyme CPSI.47
In the modiﬁed eQTL analysis, several cis-acting variants
that were associated with altered gene expression were identi-
ﬁed (Supporting Information Table S11). The most interest-
ing ﬁnding was the association of rs4793943 with ZNF652
expression. This interaction may alter the TF function of
ZNF652, thereby modulating susceptibility to PrCa. Data
from RegulomeDB suggest that rs4793943 may have a more
generalized role in transcriptional regulation. It is located
within the binding site of ZNF26339 and it overlaps with
HOXA9 and HOXB13 binding motifs. Both of these TFs
have been connected with PrCa initiation and progression.2,48
Furthermore, our data provided suggestive evidence that
rs4793976 is an eQTL regulating the expression of SPOP
(Supporting Information Table S11). SPOP, a putative tumor
suppressor gene, is frequently mutated in localized and
advanced prostate tumors.30 SPOP mutations are regarded as
driver lesions in prostate carcinogenesis31 and the loss of
SPOP expression may contribute to PrCa development.49
While interpreting the eQTL results, it is important to
recall that the signiﬁcant DE genes and SNP-gene
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associations could be identiﬁed merely by chance. The num-
ber of observed signiﬁcant test results lies in the same magni-
tude as the number of expected signiﬁcant test results, if the
null hypothesis would hold for all performed tests. However,
the risk of an excess of false positive results was accepted in
favor of minimizing the risk of obtaining too many false neg-
ative results. Although several of the SNP-gene connections
detected in this study achieved statistical signiﬁcance, this
does not necessarily indicate biological signiﬁcance. Neither
is the mechanism of interaction between the individual
eQTLs and their target genes currently known. Further vali-
dation with independent datasets is required to conﬁrm the
signiﬁcance of the SNP-gene associations identiﬁed here.
In conclusion, the present study demonstrated that next-
generation sequencing is a valid and reliable approach for
identifying novel disease-associated variants and mutations,
especially those rare enough to escape the resolution of
GWAS. In contrast to imputation and related prediction-
based methods, next-generation sequencing methods provide
true genotype data with a minimal error rate. The integrated
analysis of rare and common variants with gene expression
data generated unique knowledge of PrCa-associated variants
with effects at the transcriptional level. This study provided a
broader view of the causative factors in PrCa, implicating
that regulatory variants co-operating with coding variants can
modulate the inherited risk for the disease. The ﬁndings
reported here encourage further research to elucidate the reg-
ulatory networks that control PrCa initiation and
development.
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